Clinical Trial Update: Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) [Phase 2]

View source ↗

Summary

Phase 2 MATCH-Subprotocol W trial evaluating AZD4547 for cancers with FGFR genetic alterations has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematopoietic and Lymphoid Cell Neoplasm
• Lymphoma
• Malignant Solid Neoplasm
• Plasma Cell Myeloma

Drugs mentioned

• AZD4547

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2021-06-29